ArticleObesity medicine2021
Therapeutic use of Guggulsterone in COVID-19 induced obesity (COVIBESITY) and significant role in immunomodulatory effect.
Article in Obesity medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 39 citations in OpenAlex.
- PEBL, a component-based Chinese medicine, reduces virus-induced acute lung injury by targeting FXR to decrease ACE2 levels.Journal of advanced research · 2026Article
- Virtual Screening of Phytochemicals From Medicinal Plants as Promising PDE5 Inhibitors Against Erectile Dysfunction.Food science & nutrition · 2026Article
- Formulation and Evaluation of Microsponges-loaded Transdermal Gel for the Management of Osteoarthritis.Recent advances in inflammation & allergy drug discovery · 2025Article
- Isolation of 6-gingerol and semi-synthesis of 1,4-benzodiazepines derivatives: An in-situ pharmacokinetics properties, molecular docking and molecular dynamics simulation assessments.Saudi journal of biological sciences · 2024Article
- A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection.Inflammopharmacology · 2023Review
- Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology.PloS one · 2023Article
- Computational Bioprospecting Guggulsterone against ADP Ribose Phosphatase of SARS-CoV-2.Molecules (Basel, Switzerland) · 2022Article
- Pandemic-induced stress and obesity leading to abnormal uterine bleeding: A prospective study.Health science reports · 2022Article
- Network pharmacology and in silico pharmacokinetic prediction of Ozanimod in the management of ulcerative colitis: A computational study.Health science reports · 2022Article
- Junk food-induced obesity- a growing threat to youngsters during the pandemic.Obesity medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 has emerged as a major cause of health crisis around the world. Psychosocial, Behavioral and metabolic changes especially weight gain, among variety of population was produced in this pandemic, through variety of mechanisms. Hyperlipidemia is one of the major issues that result in serious cardiovascular complications. Governmental strategies to minimize the spread of COVID-19 through closures, lockdowns, and alterations in social interaction have complicated weight management efforts. And immunity being the need of the hour has to be improved to prevent the infection. Guggulsterone (GS) isomers are major bioactive compounds present in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.